Keratoconjunctivitis Sicca (Dry Eye) is an indication for drug development with over 170 pipeline drugs currently active. According to GlobalData, preregistered drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 87.5% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Keratoconjunctivitis Sicca (Dry Eye) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Keratoconjunctivitis Sicca (Dry Eye) overview

Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues, and immunosuppressants.

For a complete picture of PTSR and LoA scores for drugs in Keratoconjunctivitis Sicca (Dry Eye), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.